The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Patiromer (Veltassa®) has been rejected for use in the treatment of hyperkalaemia in adults. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC. It should be noted the NICE Guidance exists for England and Wales that contains specific recommendations for use.
Romosozumab (Evenity®) has been accepted for restricted use in the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. The restriction limits use to women who have experienced a fragility fracture and are at imminent risk of another fragility fracture (within 24 months).
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - October 2020||Drug Safety Update - November 2020 »|